BACKGROUND: Scarce data exist concerning the outcome of very elderly patients with head and neck squamous cell carcinoma (HNSCC). METHODS: The clinical files of 316 patients aged > or = 80 years with HNSCC who were included in the authors' hospital database between 1987 and 2006 were reviewed retrospectively. RESULTS: Approximately 88% of patients received locoregional treatment, 31% of patients underwent surgery, and 57% of patients received definitive radiotherapy. The median disease-specific survival (DSS) was 21.3 months, and a plateau was observed after 5 years. The median overall survival (OS) was 13.0 months. Both the median DSS and the median OS were longer for patients with stage I/II HNSCC than for patients with stage III/IV HNSCC (median DSS, not reached vs 11.4 months; P < .001; median OS, 41.9 months vs 7.9 months; P < .001). On multivariate analysis, stage I/II disease, treatment with curative intent, and evidence of locoregional control were independent predictors of improved survival. CONCLUSIONS: The outcome of patients with stage I/II HNSCC aged > or = 80 years was similar to that of younger patients, and the current results indicated that age should not be used to deny them optimal treatment. Elderly patients with stage III/IV HNSCC had poor survival. Geriatric tools should be used to identify elderly patients who are eligible for optimal locoregional treatment. (c) 2008 American Cancer Society
BACKGROUND: Scarce data exist concerning the outcome of very elderly patients with head and neck squamous cell carcinoma (HNSCC). METHODS: The clinical files of 316 patients aged > or = 80 years with HNSCC who were included in the authors' hospital database between 1987 and 2006 were reviewed retrospectively. RESULTS: Approximately 88% of patients received locoregional treatment, 31% of patients underwent surgery, and 57% of patients received definitive radiotherapy. The median disease-specific survival (DSS) was 21.3 months, and a plateau was observed after 5 years. The median overall survival (OS) was 13.0 months. Both the median DSS and the median OS were longer for patients with stage I/II HNSCC than for patients with stage III/IV HNSCC (median DSS, not reached vs 11.4 months; P < .001; median OS, 41.9 months vs 7.9 months; P < .001). On multivariate analysis, stage I/II disease, treatment with curative intent, and evidence of locoregional control were independent predictors of improved survival. CONCLUSIONS: The outcome of patients with stage I/II HNSCC aged > or = 80 years was similar to that of younger patients, and the current results indicated that age should not be used to deny them optimal treatment. Elderly patients with stage III/IV HNSCC had poor survival. Geriatric tools should be used to identify elderly patients who are eligible for optimal locoregional treatment. (c) 2008 American Cancer Society
Authors: David Goldenberg; Heath Mackley; Wayne Koch; Darrin V Bann; Eric W Schaefer; Christopher S Hollenbeak Journal: Oral Oncol Date: 2014-08-19 Impact factor: 5.337
Authors: Virginia A Moye; Sindhu Chandramouleeswaran; Ni Zhao; Hyman B Muss; Mark C Weissler; David N Hayes; Jose P Zevallos Journal: Oncologist Date: 2015-01-12
Authors: Romain Rivoirard; Coralie Moncharmont; Avi Assouline; Pierre Auberdiac; Benoite Mery; Alexander Tuan Falk; Pierre Annède; Jane-Chloé Trone; Jean-Baptiste Guy; Nicolas Vial; Pierre Fournel; Yacine Merrouche; Cyrus Chargari; Nicolas Magné Journal: Eur Arch Otorhinolaryngol Date: 2014-04-02 Impact factor: 2.503